journal article·2016-04

Synergistic anti-tumor activity through combinational intratumoral injection of an in-situ injectable drug depot

Da Yeon Kim, Doo Yeon Kwon, Jin Seon Kwon, Ji Hoon Park, Seung Hun Park, Hyun Ju Oh, Jae Ho Kim, Byoung Hyun Min, Kinam Park, Moon Suk Kim

Biomaterials· Volume 85
Publisher page

Abstract

Here, we describe combinational chemotherapy via intratumoral injection of doxorubicin (Dox) and 5-fluorouracil (Fu) to enhance the efficacy and reduce the toxicity of systemically administered Fu and Dox in cancer patients. As the key concept in this work, mixture formulations of Dox-loaded microcapsules (Dox-M) and Fu-loaded Pluronic(®) hydrogels (Fu-HP) or Fu-loaded diblock copolymer hydrogels (Fu-HC) have been employed as drug depots. The in vitro and in vivo drug depot was designed as a formulation of Dox-M dispersed inside an outer shell of Fu-HP or Fu-HC after injection. The Dox-M/Fu-HP and Dox-M/Fu-HC formulations are free flowing at room temperature, indicating injectability, and formed a structural gelatinous depot in vitro and in vivo at body temperature. The Fu-HP, Fu-HC, Dox-M/Fu-HP, Dox-M/Fu-HC, and Dox-M formulations were easily injected into tumor centers in mice using a needle. Dox-M/Fu-HC produced more significant inhibitory effects against tumor growth than that by Dox-M/Fu-HP, while Fu-HP, Fu-HC and Dox-M had the weakest inhibitory effects of the tested treatments. The in vivo study of Dox and Fu biodistribution showed that high Dox and Fu concentrations were maintained in the target tumor only, while distribution to normal tissues was not observed, indicating that Dox and Fu concentrations below their toxic plasma concentrations should not cause significant systemic toxicity. The Dox-M/Fu-HP and Dox-M/Fu-HC drug depots described in this work showed excellent performance as chemotherapeutic delivery systems. The results reported here indicate that intratumoral injection using combination chemotherapy with Dox-M/Fu-HP or Dox-M/Fu-HC could be of translational research by enhancing the synergistic inhibitory effects of Dox and Fu on tumor growth, while reducing their systemic toxicity in cancer patients.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · 3D Printing in Biomedical Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (24)

Show source-provided references
1. Exploiting the critical perioperative period to improve long-term cancer outcomes10.1038/nrclinonc.2014.224 ↗
2. Melanoma adjuvant therapy
3. Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy10.1016/j.biomaterials.2015.07.027 ↗
4. PLK1shRNA and doxorubicin co-loaded thermosensitive PLGA-PEG-PLGA hydrogels for osteosarcoma treatment10.1016/j.biomaterials.2014.06.045 ↗
5. Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice
6. Doxorubicin conjugated phospholipid prodrugs as smart nanomedicine platforms for cancer therapy10.1039/C4TB01984A ↗
7. 5-Fluorouracil toxicity and dihydropyrimidine dehydrogenase enzyme: implications for practice10.1188/14.CJON.581-585 ↗
8. Versatile preparation of intracellular-acidity-sensitive oxime-linked polysaccharide-doxorubicin conjugate for malignancy therapeutic10.1016/j.biomaterials.2015.03.021 ↗
9. Preliminary pharmacology of galactosylated chitosan/5-fluorouracil nanoparticles and its inhibition of hepatocellular carcinoma in mice10.4161/cbt.22001 ↗
10. A 5-fluorouracil-loaded polydioxanone weft-knitted stent for the treatment of colorectal cancer10.1016/j.biomaterials.2013.08.055 ↗
11. 5-fluorouracil induced cardiotoxicity: review of the literature10.5603/CJ.2012.0084 ↗
12. The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors10.1158/1078-0432.CCR-05-1664 ↗
13. Bioactive factor delivery strategies from engineered polymer hydrogels for therapeutic medicine10.1016/j.progpolymsci.2013.12.001 ↗
14. Injectable in situ–forming hydrogels for regenerative medicines10.1080/15583724.2014.983244 ↗
15. Thermo-responsive injectable MPEG-polyester diblock copolymers for sustained drug release10.3390/polym6102670 ↗
16. Injectable intratumoral hydrogel as 5-fluorouracil drug depot10.1016/j.biomaterials.2013.01.006 ↗
17. In vivo efficacy of an intratumorally injected in situ-forming doxorubicin/poly(ethylene glycol)-b-polycaprolactone diblock copolymer10.1016/j.biomaterials.2011.03.007 ↗
18. Injectable in situ-forming hydrogels for a suppression of drug burst from drug-loaded microcapsules10.1039/c2sm25566a ↗
19. BSA-FITC loaded microcapsules for in vivo delivery10.1016/j.biomaterials.2008.10.030 ↗
20. Insulin-loaded microcapsules for in vivo delivery10.1021/mp800087t ↗
21. Genipin-crosslinked catechol-chitosan mucoadhesive hydrogels for buccal drug delivery10.1016/j.biomaterials.2014.10.024 ↗
22. In vitro and in vivo release of albumin using biodegradable MPEG-PCL diblock copolymer as an in situ gel forming carrier10.1021/bm060991u ↗
23. Double emulsion solvent evaporation techniques used for drug encapsulation10.1016/j.ijpharm.2015.10.057 ↗
24. A novel doxorubicin-loaded in situ forming gel based high concentration of phospholipid for intratumoral drug delivery10.1021/mp500019p ↗